Saturday 17 October 2026
Export INBX’s income statement to Excel — free account
Inhibrx Biosciences, Inc.
INBX Healthcare Biotechnology
Inhibrx Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 550.0% from fiscal 2024. In the quarter to June 2026, revenue grew 992.4%, EPS fell 26.5%, free cash flow was flat and total debt rose 77.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
89.83
0.67
−0.74%
Follow INBX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
4.28 | 3.68 | 6.10 | 4.76 | |
Current Ratio |
4.49 | 3.93 | 6.46 | 5.07 | |
Net Debt/EBITDA |
1.60 | 0.78 | (0.44) | (1.36) | |
Debt/Assets |
56.30% | 68.65% | 95.12% | 114.31% | |
Debt/Equity |
2.71 | 12.58 | (8.32) | (3.33) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.96 | 0.92 | 1.14 | 0.82 | |
Capex/Depreciation |
(0.01) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(10.63) | (9.71) | (8.81) | (5.65) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.19) | (1.94) | (2.44) | (1.91) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.19) | (1.94) | (2.44) | (1.91) | |
Cash per Share |
9.89 | 8.02 | 10.37 | 8.51 | |
Shareholders Equity per Share |
2.38 | 0.52 | (1.35) | (3.38) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.38 | 0.52 | (1.35) | (3.38) | |
Free Cash Flow |
(33.83) | (30.12) | (38.03) | (29.92) | |
Working Capital |
125.44 | 99.03 | 144.83 | 114.15 | |
Capital Expenditures |
(0.01) | 0.00 | — | — | |
Net Current Asset Value |
20.78 | (5.65) | (33.66) | (64.99) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
0.98 | 0.30 | 0.20 | 0.55 | |
Average Payables |
9.57 | 7.59 | 8.83 | 9.05 | |
Average Assets |
200.02 | 163.62 | 213.30 | 183.17 | |
Average Common Equity |
107.65 | 70.79 | 36.70 | 7.79 |
Columns are period end dates